Aim2 Couples With Ube2i for Sumoylation-Mediated Repression of Interferon Signatures in Systemic Lupus Erythematosus.
Ailing LuShuxian WuJunling NiuMengmeng CuiMengdan ChenWilliam L ClappBetsy J BarnesGuang-Xun MengPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
The present study demonstrates a critical role for Aim2 in an optimal Ube2i-mediated sumoylation-based suppression of type I IFN generation and development of SLE. As such, the Aim2-Ube2i axis can thus be a novel target for intervention in SLE.